is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to or fax to (405) 239-2112. 

Current Cases

Aerie Pharmaceuticals, Inc. [NASDAQ: AERI]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Aerie Pharmaceuticals, Inc.


Oklahoma City, OK (May 4, 2015) – On April 29, 2015, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against Aerie Pharmaceuticals, Inc. (NASDAQ: AERI).  The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is August 6, 2014 through April 23, 2015.  More specifically, this litigation was filed because on April 23, 2015, the Company issued a press release announcing the results of its first Phase 3 registration trial for RhopressaTM.  According to the release, “[T]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of  IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.”  On this news, the Company’s shares declined to close at $12.87. 


Plaintiff seeks to recover damages on behalf of all Aerie Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above.  You may move the Court no later than Monday, June 29, 2015 to serve as a lead plaintiff for the entire Class.  However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click hereto obtain an investor certification.  Once complete, please email this form to, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN:  Robin.

Copyright © 2018 Federman & Sherwood. All Rights Reserved.